Last reviewed · How we verify
GC3110A(Quadrivalent)
GC3110A(Quadrivalent) is a Vaccine Biologic drug developed by Green Cross Corporation. It is currently in Phase 3 development for Indication not publicly specified for GC3110A(Quadrivalent) in Phase 3. Also known as: GC3110A.
GC3110A is a quadrivalent vaccine designed to stimulate immune responses against multiple disease targets.
GC3110A is a quadrivalent vaccine designed to stimulate immune responses against multiple disease targets. Used for Indication not publicly specified for GC3110A(Quadrivalent) in Phase 3.
-
Baseline phase 3 → approval rate
+58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas). -
Immunology slight uplift
+1.0pp
Mature endpoint landscape (ACR, DAS28, PASI) makes immunology approvals slightly more predictable.
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2028–2030 | — |
| EMA | EU | 2029–2031 | +0.7 yr |
| MHRA | GB | 2029–2031 | +0.7 yr |
| Health Canada | CA | 2029–2032 | +0.9 yr |
| TGA | AU | 2029–2032 | +1.2 yr |
| PMDA | JP | 2029–2032 | +1.5 yr |
| NMPA | CN | 2030–2033 | +2.3 yr |
| MFDS | KR | 2029–2032 | +1.4 yr |
| CDSCO | IN | 2029–2033 | +1.8 yr |
| ANVISA | BR | 2030–2033 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | GC3110A(Quadrivalent) |
|---|---|
| Also known as | GC3110A |
| Sponsor | Green Cross Corporation |
| Drug class | Vaccine |
| Modality | Biologic |
| Therapeutic area | Immunology |
| Phase | Phase 3 |
Mechanism of action
As a quadrivalent vaccine formulation, GC3110A likely combines antigens or immunogenic components targeting four distinct pathogens or disease-related targets to elicit protective humoral and/or cellular immunity. The specific mechanism depends on the vaccine platform and target antigens, which are not publicly detailed for this investigational candidate.
Approved indications
- Indication not publicly specified for GC3110A(Quadrivalent) in Phase 3
Common side effects
Key clinical trials
- A Study to Evaluate the Efficacy and Safety of GC3110A in Healthy Infants From 6 Months to 35 Months of Age (PHASE3)
- A Study to Evaluate the Efficacy and Safety of GC3110A in Healthy Subjects Aged 65 Years and Older (PHASE3)
- A Multicenter, Double-blind, Parallel Phase III Study (PHASE3)
- A Phase I/IIa Study of GC3110A (Quadrivalent Influenza Vaccine) (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- GC3110A(Quadrivalent) CI brief — competitive landscape report
- GC3110A(Quadrivalent) updates RSS · CI watch RSS
- Green Cross Corporation portfolio CI
Frequently asked questions about GC3110A(Quadrivalent)
What is GC3110A(Quadrivalent)?
How does GC3110A(Quadrivalent) work?
What is GC3110A(Quadrivalent) used for?
Who makes GC3110A(Quadrivalent)?
Is GC3110A(Quadrivalent) also known as anything else?
What drug class is GC3110A(Quadrivalent) in?
What development phase is GC3110A(Quadrivalent) in?
Related
- Drug class: All Vaccine drugs
- Manufacturer: Green Cross Corporation — full pipeline
- Therapeutic area: All drugs in Immunology
- Indication: Drugs for Indication not publicly specified for GC3110A(Quadrivalent) in Phase 3
- Also known as: GC3110A
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing